Exhibit 10.1 AGREEMENT OF SALE AND PURCHASEAgreement of Sale and Purchase • May 15th, 2003 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances • California
Contract Type FiledMay 15th, 2003 Company Industry Jurisdiction
EXHIBIT 10.5 FIRST AMENDMENT TO SETTLEMENT AGREEMENT THIS FIRST AMENDMENT TO SETTLEMENT AGREEMENT ("First Amendment"), effective as of October 1, 2003, is made by and among Applera Corporation, a Delaware corporation, acting through its Applied...Settlement Agreement • November 9th, 2004 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 9th, 2004 Company Industry
AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 26, 2006 BY AND AMONG SIEMENS MEDICAL SOLUTIONS USA, INC. DRESDEN ACQUISITION CORPORATION AND DIAGNOSTIC PRODUCTS CORPORATIONAgreement and Plan of Merger • May 1st, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances • California
Contract Type FiledMay 1st, 2006 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 26, 2006, is by and among Siemens Medical Solutions USA, Inc., a Delaware corporation (the “Purchaser”), Dresden Acquisition Corporation, a California corporation and a wholly-owned subsidiary of the Purchaser (“Merger Sub”), and Diagnostic Products Corporation, a California corporation (the “Company” and, together with the Purchaser and Merger Sub, the “Parties” and each, a “Party”).
STANDARD INDUSTRIAL LEASE OPTION EXERCISEIndustrial Lease Option Exercise • May 10th, 2005 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Contract Type FiledMay 10th, 2005 Company IndustryThis Exercise of Option is made with respect to that certain Standard Industrial Lease dated February 18, 1991 (the “Lease”) between 5700 West 96th Street, a California general partnership (“Lessor”), and Diagnostic Products Corporation, a California corporation (“Lessee”), as amended pursuant to that certain Second Addendum to Standard Industrial Lease between Lessor and Lessee dated April 1, 2002 (the “Addendum”).
SECOND ADDENDUM TO STANDARD INDUSTRIAL LEASEDiagnostic Products Corp • May 14th, 2002 • In vitro & in vivo diagnostic substances
Company FiledMay 14th, 2002 IndustryThis rider to the lease is dated April 1, 2002 and between lessors by Michael Ziering, general partner, 5700 West 96th Street Partnership, and by James Brill, VP Finance and CFO of Diagnostic Products Corporation.
AMENDMENT TO LEASELease • May 10th, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Contract Type FiledMay 10th, 2006 Company IndustryAMENDMENT TO LEASE (the “Amendment”) dated as of April 26, 2006, by and between 5700 WEST 96th STREET, a California general partnership (“Landlord”) and DIAGNOSTIC PRODUCTS CORPORATION, a California corporation (“Tenant”).
DIAGNOSTIC PRODUCTS CORPORATION 1997 STOCK OPTION PLAN INCENTIVE STOCK OPTION AGREEMENTStock Option Plan Incentive Stock Option Agreement • November 9th, 2004 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 9th, 2004 Company IndustryDIAGNOSTIC PRODUCTS CORPORATION (the “Corporation”) hereby grants to (the “Optionee”), pursuant to the 1997 Stock Option Plan (the “Plan”), an incentive option to purchase shares of Common Stock, without par value, of the Corporation at a price of $ per share (the “Option”). This Agreement is specifically subject to and governed by all of the terms and conditions of the Plan, as from time to time amended, with the same force and effect as if fully set forth herein. Capitalized terms which have not been defined herein shall have the meanings given them in the Plan. In the event of any conflict between this Agreement and the Plan, the Plan shall govern. A copy of the plan is available for inspection at the Corporation’s executive office.
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • May 2nd, 2006 • Diagnostic Products Corp • In vitro & in vivo diagnostic substances
Contract Type FiledMay 2nd, 2006 Company IndustryTHIS CHANGE IN CONTROL SEVERANCE AGREEMENT is made and entered into by and between Diagnostic Products Corporation, a California corporation (hereinafter referred to as the “Company”) and (hereinafter referred to as the “Executive”).